Related Experiment Video
Updated: Nov 25, 2025
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.2K
GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas
Chelsea Marcus1, Georgios A Maragkos2, Ron L Alterman3
1Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215, United States; Harvard Medical School, 25 Shattuck St., Boston, MA 02115, United States.
Summary
Classifying primary CNS lymphoma (PCNSL) into germinal center B-cell (GCB) and non-GCB subtypes may predict patient outcomes. GCB-type PCNSLs show a better prognosis than non-GCB types.
Area of Science:
- Neuro-oncology
- Hematology
- Pathology
Background:
- Primary CNS lymphomas (PCNSLs) are aggressive diffuse large B-cell lymphomas (DLBCLs) with poor prognoses.
- Subtyping DLBCL into germinal center B-cell (GCB) and activated B-cell (non-GCB) has prognostic value in systemic disease.
Purpose of the Study:
- To investigate if GCB versus non-GCB classification in PCNSLs holds similar prognostic significance.
- To determine the prognostic value of GCB/non-GCB subtypes in PCNSLs.
Main Methods:
- Analysis of clinical, radiological, and histological data from 24 patients with biopsy-confirmed PCNSL.
- Classification of PCNSLs into GCB and non-GCB subtypes using the Hans algorithm.
Main Results:
- GCB-type PCNSLs showed a significantly better prognosis, with all patients alive at 22 months follow-up.
- Non-GCB-type PCNSLs had a median survival of 11 months, with only 39% alive at 15 months.
- Younger patients (<70 years) had longer survival (29 months) compared to older patients (8.8 months).
Conclusions:
- GCB versus non-GCB classification may help stratify PCNSL patients into distinct prognostic groups.
- This subtyping strategy could aid in personalized treatment approaches for PCNSL.
